Country: Bretland
Tungumál: enska
Heimild: MHRA (Medicines & Healthcare Products Regulatory Agency)
Propylthiouracil
Halewood Chemicals Ltd
H03BA02
Propylthiouracil
50mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 06020200; GTIN: 5060306430302 5060306430241
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again • If you have any further questions, ask your doctor, pharmacist or nurse • This medicine has been prescribed for you only. Do not pass it on to others as it may harm them, even if their signs of illness are the same as yours • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4 • Propylthiouracil 50 mg Tablets are called ‘Propylthiouracil Tablets’ in this leaflet WHAT IS IN THIS LEAFLET 1. What Propylthiouracil Tablets are and what they are used for 2. What you need to know before you take Propylthiouracil Tablets 3. How to take Propylthiouracil Tablets 4. Possible side effects 5. How to store Propylthiouracil Tablets 6. Contents of the pack and other information 1. WHAT PROPYLTHIOURACIL TABLETS ARE AND WHAT THEY ARE USED FOR Propylthiouracil Tablets contains the active substance propylthiouracil. Propylthiouracil is used to treat hyperthyroidism in adults (including the elderly) and in children and adolescents aged 6 to 18 years. Hyperthyroidism is a condition where the thyroid gland is overactive and makes too much thyroid hormone called thyroxine. Thyroxine helps to regulate the body's growth and metabolism. This medicine helps restore thyroxine levels in your bloodstream to normal levels: it may take several weeks for this to happen. Hence it is important to keep taking the medicine every day. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PROPYLTHIOURACIL TABLETS DO NOT TAKE PROPYLTHIOURACIL TABLETS: • if you are allergic to propylthiouracil or any of the other ingredients in this medicine (listed in section 6) • if you have ever had a severe allergic reaction to propylthiouracil, including a reduced white blood cell count, liver problems, inflamed blood vessels and kidney problems WARNINGS AND PRECAUTIONS Talk to your docto Lestu allt skjalið
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Propylthiouracil 50 mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of propylthiouracil. Excipient with known effect: Each tablet contains 31.8 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White, circular biconvex tablet of approximately 6.5 mm by 3 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Propylthiouracil 50 mg Tablets is indicated in adults (including the elderly), children and adolescents aged 6 to 18 years, for the treatment of hyperthyroidism. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults, including the elderly _ Initially 300 to 600 mg daily, once daily or in divided doses until the patient becomes euthyroid. When the condition is controlled (usually after 1-2 months), the dose is reduced to 50 to 150 mg daily and continued for 1-2 years. _Patients with renal failure_ GFR 10 to 50 ml/min, 75% dose. GFR < 10 ml/min, 50% dose. _Patients with hepatic disease_ Reduced dose. _Paediatric population _ Children under 6 years of age: Propylthiouracil 50 mg Tablets should not be used in children under 6 years of age because of safety concerns. Children aged 6 to 10 years: Initially 50 to 150 mg once daily or in divided doses. Children aged over 10 years: Initially 150 to 300 mg once daily or in divided doses. Method of administration Oral use. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. Previous severe hypersensitivity reaction e.g. agranulocytosis, hepatitis, vasculitis and nephritis with propylthiouracil. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Due to the risk of agranulocytosis it is advised that patients should be warned to report to their doctor in the event of a sore throat, fever, mouth ulcers, bruising, malaise, non-specific illness or other symptoms of infection immediately. A full blood count should be performed and treatment should be dis Lestu allt skjalið